The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
Clinical trial NCT06819514 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06819514
- Sponsor
- Guangzhou Jiayin Biotech Ltd
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2028-03-15
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.